A prediction model for treatment decisions in high-grade extremity soft-tissue sarcomas: Personalised sarcoma care (PERSARC)

Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi‐centre study

“…These issues may be addressed in the frame of a prospective study, similar to the study by Puri et al, 26 with patients assigned to various standardised protocols differing in intervals and methodology. Recently, two apps (Sarculator, 27 PERSARC 28 ) have been developed based on a thorough analysis of the risk of local recurrence and distant metastasis as well as OS in patients with eSTS, aiming at individualising patient treatment and aftercare. Based on these advancements, follow‐up may in the future slightly differ from the proposed ESMO guidelines, 12 taking into account individual risk factors altering rates of LR and DM, as well as overall prognosis.…”

“…Soft tissue sarcomas of the extremity and trunk (STS) are rare tumours with an estimated incidence of 2.4 cases per 100 000 persons per year 1 . About 15% of STS‐patients develop local recurrences and 30% distant metastases at 5 years, most commonly to the lungs 2‐5 . Other metastatic sites are described (bone and lymph nodes), however abdominal metastases (AM) from STS, are very uncommon 6,7 .…”

Prognostic models for RPS patients—Attempting to predict patient outcomes

“…The use of smartphone‐based app facilitated the computation of patients’ prognosis. Smartphones are changing the daily life of physicians and prognostic apps are becoming available also for STS patients …”

“…In parallel, site-specific prognostic tools for extremity or retroperitoneal STS have also been built. 17,18,20,21,[31][32][33][34][35][36] When specifically focused on a patient-population defined according to patients and tumor characteristics such as site or histology, nomograms allow predictions based on prognostic features relevant in that specific setting. For example, a nomogram for synovial sarcoma can take into consideration the histologic variant (monophasic vs biphasic) while a nomogram for uterine LMS can factor the presence of cervical involvement.…”

“…Initially, nomograms were designed to incorporate all histological subtypes and sites, however, histology‐specific nomograms for liposarcoma, synovial sarcoma, rhabdomyosarcoma, desmoid‐type fibromatosis, breast phyllodes tumors, and uterine leiomyosarcoma have been developed. In parallel, site‐specific prognostic tools for extremity or retroperitoneal STS have also been built …”